Search

everythinglearnresearchcommunity

for

Search:↓

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Higher DHEA-S levels are linked to smaller ovarian volume in women with PCOS.

High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.

Hirsute women with ovarian-sourced hirsutism are more likely to have irregular periods, with higher BMI and altered hormone ratios.

PCOS women have more severe metabolic issues and higher androgen levels than hyperandrogenic women without PCOS.

Lean and obese women with PCOS have similar levels of insulin resistance, indicating it's a core aspect of the condition.

Hormone imbalances from the pituitary, thyroid, and adrenal glands can cause infertility, but treating these disorders can improve fertility.

The more lipophilic the progesterone derivative, the better it binds to androgen receptors and has antiandrogenic effects.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Insulin resistance might not be enough to worsen blood vessel function in young, nonobese women with polycystic ovary syndrome.

A higher testosterone/dihydrotestosterone ratio in PCOS patients may indicate worse metabolic health.

Early life factors, including a mother's health and environment, can affect the chances of developing polycystic ovary syndrome later in life.

PRP injections did not significantly improve ovarian function in women with low ovarian reserve.

The contraceptive reduced hair growth and altered hormone levels in hirsute women.

Women with idiopathic hirsutism and PCOS have higher RBP4 levels, and PCOS is linked to greater insulin resistance; weight management may help both conditions.

Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.

The 2018 guideline for PCOS suggests new diagnostic criteria and treatments, but recognizes the need for more research.

Women with PCOS have a similar chance of getting pregnant using assisted reproductive treatment as those without PCOS.

Topical estrogen treatments did not change hair growth in certain mouse strains, questioning previous findings on their role in hair growth control.

Larger ovarian size is linked to higher insulin resistance in women with PCOS.

Different forms of the Vitamin D receptor can impact metabolic and hormone issues in Polycystic Ovary Syndrome.

Vitamin D supplements increased ovulation rates in women with PCOS who were vitamin D deficient.

PCOS is a major cause of infertility and requires personalized treatment.

Metformin taken during pregnancy increases SHBG in newborns but doesn't change other hormone levels in mothers or babies.

MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.

Late onset of first period and irregular development of sexual traits in teenage girls can lead to poorer reproductive health.

Vitamin D levels do not significantly relate to the causes of PCOS or DOR in infertile patients.

Obesity greatly affects polycystic ovarian syndrome, and losing weight should be the first treatment for obese patients to improve their chances of ovulation and pregnancy.

Treating PCOS patients with HP HMG significantly raises the risk of ovarian hyperstimulation syndrome, needing careful dose management.